Search

Displaying results 2321 - 2330 of 4004 in total
  1. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    FDA approved on August 13, 2009.

  2. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.

  3. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin.

  4. Drug

    Isopropyl beta-D-thiogalactopyranoside

    go.drugbank.com/drugs/DB01862
    Experimental

    A non-metabolizable galactose analog that induces expression of the LAC operon.

  5. Drug

    Naveglitazar

    go.drugbank.com/drugs/DB12662
    Investigational

    Naveglitazar has been used in trials studying the treatment of Diabetes Mellitus, Non-Insulin-Dependent.

  6. Drug

    Bouteloua gracilis pollen

    go.drugbank.com/drugs/DB10715
    Approved

    Bouteloua gracilis pollen is the pollen of the Bouteloua gracilis plant. Bouteloua gracilis pollen is mainly used in allergenic testing.

    Categories: Non-Standardized Pollen Allergenic Extract
  7. Drug

    Phalaris minor pollen

    go.drugbank.com/drugs/DB10963
    Approved

    Phalaris minor pollen is the pollen of the Phalaris minor plant. Phalaris minor pollen is mainly used in allergenic testing.

    Categories: Non-Standardized Pollen Allergenic Extract
  8. Drug

    Finasteride

    go.drugbank.com/drugs/DB01216
    ApprovedInvestigational

    Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in

  9. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibruti...

  10. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).